Efficacy and safety of ivonescimab in non-small cell lung cancer: a systematic review and meta-analysis of emerging clinical data.

ABSTRACT:

Introduction

Ivonescimab (AK112), a novel bispecific antibody targeting PD-1 and VEGF, has emerged as a promising therapeutic agent in the treatment of non-small cell lung cancer (NSCLC). This study aims to comprehensively evaluate its efficacy and safety.

Materials and methods

A comprehensive literature search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library (from inception to January 2026) to identify studies reporting the clinical efficacy and safety outcomes of AK112 in NSCLC. Pooled analyses were conducted for efficacy endpoints, including objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS), as well as adverse events (AEs). For randomized controlled trials (RCTs), odds ratios (ORs) and hazard ratios (HR

SUBMITTER: Dai Y 

PROVIDER: S-EPMC12909539 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature